Search Results

You are looking at 1 - 3 of 3 items for

  • Author or Editor: Julie L. Webb x
  • Refine by Access: All Content x
Clear All Modify Search
History and Clinical Findings

A 4-year-old spayed female indoor-only domestic shorthair cat was evaluated at the University of Wisconsin because of a 1-week history of progressive respiratory difficulty. The cat was being treated by the referring veterinarian with antimicrobials (metronidazole and orbifloxacin) as well as furosemide, with a resultant slight initial improvement in clinical signs. However, radiographic views obtained by the referring veterinarian after initiation of treatment revealed a dorsally deviated and compressed trachea, pleural effusion, and middle lung lobe consolidation.

On the day of the referral evaluation, the cat became anorectic and developed respiratory distress. On physical examination, the

Restricted access
in Journal of the American Veterinary Medical Association

Abstract

OBJECTIVE To evaluate urine variables in chinchillas (Chinchilla lanigera).

DESIGN Evaluation study.

SAMPLE Urine samples from 41 chinchillas.

PROCEDURES Voided urine samples were collected from clinically normal chinchillas that were exhibited during a breeder exposition. Urinalysis was performed within 1 hour after collection. Urine specific gravity (USG) was measured before and after centrifugation with a handheld veterinary refractometer. Urine dipstick analysis and microscopic sedimentation examination were performed on all samples. Additionally, a urine sulfosalicylic acid (SSA) precipitation test and quantitative protein analysis were performed on samples with sufficient volume.

RESULTS 17 of 41 (41%) samples had a USG ≥ 1.050, and USG ranged from 1.014 to > 1.060. The USG before centrifugation did not differ significantly from that after centrifugation. Protein was detected in all urine samples on dipstick analysis. The SSA precipitation test yielded negative results for all samples tested. Results of the quantitative protein analyses were not correlated with the results of the dipstick analyses or SSA tests. The recorded pH for all samples was 8.5, which was the upper limit of detection for the reagent strip. Glucose and ketones were detected in 5 and 6 samples, respectively. Crystals were observed in 28 of 41 (68%) samples; 27 of those samples contained amorphous crystals.

CONCLUSIONS AND CLINICAL RELEVANCE Urinalysis results for clinically normal chinchillas were provided. For chinchilla urine samples, measurement of USG by refractometry prior to centrifugation is acceptable and protein concentration should be determined by quantitative protein analysis rather than dipstick analysis or the SSA test.

Restricted access
in Journal of the American Veterinary Medical Association

Abstract

Objective—To determine the pharmacokinetics and safety of orally administered voriconazole in African grey parrots.

Animals—20 clinically normal Timneh African grey parrots (Psittacus erithacus timneh).

Procedures—In single-dose trials, 12 parrots were each administered 6, 12, and 18 mg of voriconazole/kg orally and plasma concentrations of voriconazole were determined via high-pressure liquid chromatography. In a multiple-dose trial, voriconazole (18 mg/kg) was administered orally to 6 birds every 12 hours for 9 days; a control group (2 birds) received tap water. Treatment effects were assessed via observation, clinicopathologic analyses (3 assessments), and measurement of trough plasma voriconazole concentrations (2 assessments).

Results—Voriconazole's elimination half-life was short (1.1 to 1.6 hours). Higher doses resulted in disproportional increases in the maximum plasma voriconazole concentration and area under the curve. Trough plasma voriconazole concentrations achieved in the multiple-dose trial were lower than those achieved after administration of single doses. Polyuria (the only adverse treatment effect) developed in treated and control birds but was more severe in the treatment group.

Conclusions and Clinical Relevance—In African grey parrots, voriconazole has dose-dependent pharmacokinetics and may induce its own metabolism. Oral administration of 12 to 18 mg of voriconazole/kg twice daily is a rational starting dose for treatment of African grey parrots infected with Aspergillus or other fungal organisms that have a minimal inhibitory concentration for voriconazole ≤ 0.4 μg/mL. Higher doses may be needed to maintain plasma voriconazole concentrations during long-term treatment. Safety and efficacy of various voriconazole treatment regimens in this species require investigation.

Full access
in American Journal of Veterinary Research